title: Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT).
abstract: Although the current literature is limited, available data suggest that (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) imaging improves the evaluation of patients with recurrent pancreatic carcinoma and cholangiocarcinoma. There is evidence that PET/CT is particularly useful in the setting of elevated tumor markers and negative or equivocal CT findings. This article reviews the nature of these carcinomas in the post-therapy setting and describes the strengths and limitations of PET/CT when used for monitoring recurrence.
authors.affiliation: Department of Radiology, Mount Sinai Medical Center, New York, NY 10029, USA.
authors.forename: Katherine
authors.initials: K
authors.lastname: Cameron
authors.forename: Sivan
authors.initials: S
authors.lastname: Golan
authors.forename: William
authors.initials: W
authors.lastname: Simpson
authors.forename: Steven
authors.initials: S
authors.lastname: Peti
authors.forename: Sasan
authors.initials: S
authors.lastname: Roayaie
authors.forename: Daniel
authors.initials: D
authors.lastname: Labow
authors.forename: Lale
authors.initials: L
authors.lastname: Kostakoglu
mesh_terms: D002277:Carcinoma / Q000000981:diagnostic imaging; D018281:Cholangiocarcinoma / Q000000981:diagnostic imaging*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D064847:Multimodal Imaging / Q000379:methods*; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18